Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

Executive Summary

In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.

Advertisement

Related Content

Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?
Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Blame The Science, Not Regulation, For Targeted Therapy Shortfalls – FDA
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
FDA's Spielberg To Focus On Cross-Center Collaboration, Hamburg Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS057060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel